Vestipitant
Vestipitant (INN)[1]:98 is a drug developed by GlaxoSmithKline which acts as a selective antagonist for the NK1 receptor. It is under development as a potential antiemetic and anxiolytic drug,[2][3] and as a treatment for tinnitus[4] and insomnia.[5]
![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C23H21F10N3O |
Molar mass | 545.416 g/mol gยทmolโ1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
![]() ![]() |
See also
References
- "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 53" (PDF). World Health Organization. Retrieved 17 November 2016.
- Reddy, GK; Gralla, RJ; Hesketh, PJ (2006). "Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis". Supportive cancer therapy. 3 (3): 140โ2. doi:10.3816/SCT.2006.n.011. PMID 18632487.
- Brocco, M; Dekeyne, A; Mannoury La Cour, C; Touzard, M; Girardon, S; Veiga, S; De Nanteuil, G; Dejong, TR; et al. (2008). "Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents". European Neuropsychopharmacology. 18 (10): 729โ50. doi:10.1016/j.euroneuro.2008.06.002. PMID 18657401.
- Clinical trial number NCT00394056 for "Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss" at ClinicalTrials.gov
- Ratti, E; et al. (December 2013). "Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia". Sleep. 36 (12): 1823โ30. doi:10.5665/sleep.3208. PMC 3825431. PMID 24293756.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.